Provided by Tiger Fintech (Singapore) Pte. Ltd.

Candel Therapeutics, Inc.

8.75
+0.810010.20%
Post-market: 8.750.00000.00%19:59 EDT
Volume:1.02M
Turnover:8.70M
Market Cap:413.31M
PE:-5.03
High:8.79
Open:7.96
Low:7.96
Close:7.94
Loading ...

Candel Therapeutics Price Target Maintained With a $19.00/Share by HC Wainwright & Co.

Dow Jones
·
20 hours ago

Promising Clinical Results and Strong Potential of Candel Therapeutics’ CAN-2409 Justify Buy Rating

TIPRANKS
·
Yesterday

BRIEF-Candel Therapeutics Q4 Net Income USD -14.073 Million

Reuters
·
Yesterday

Candel Therapeutics Q4 Net Income USD -14.073 Million

THOMSON REUTERS
·
Yesterday

Press Release: Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

Dow Jones
·
Yesterday

Candel Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
27 Feb

Candel Therapeutics Price Target Maintained With a $19.00/Share by HC Wainwright & Co.

Dow Jones
·
26 Feb

Analysts Are Bullish on Top Healthcare Stocks: Candel Therapeutics (CADL), Day One Biopharmaceuticals (DAWN)

TIPRANKS
·
26 Feb

Promising Potential of Candel Therapeutics’ CAN-2409: Analyst Recommends ‘Buy’ Based on Compelling Phase 2 Trial Results and Future Outlook

TIPRANKS
·
26 Feb

Candel Therapeutics Shares Fall After Final Pancreatic Cancer Survival Data

MT Newswires Live
·
26 Feb

Candel Therapeutics Shares Reverse Course From Premarket Gains; Last Down 4.7%

THOMSON REUTERS
·
25 Feb

Candel Therapeutics Shares up 4% Premarket After Positive Results From Early Trial of Cancer Drug

THOMSON REUTERS
·
25 Feb

Candel Therapeutics Inc - Can-2409 Associated With Favorable Safety/Tolerability Profile

THOMSON REUTERS
·
25 Feb

Candel Therapeutics Inc - Can-2409 Safety Profile Generally Favorable in Phase 2 Trial

THOMSON REUTERS
·
25 Feb

Candel Therapeutics Announces Positive Final Survival Data From Randomized Controlled Phase 2 Clinical Trial of Can-2409 in Non-Metastatic Pancreatic Cancer

THOMSON REUTERS
·
25 Feb

Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

GlobeNewswire
·
25 Feb